Helix BioPharma (FRA:HBP0) EBIT per Share : €-0.28 (TTM As of Jan. 2025)

View and export this data going back to . Start your Free Trial

What is Helix BioPharma EBIT per Share?

Helix BioPharma's EBIT per Share for the three months ended in Jan. 2025 was €-0.09. Its EBIT per Share for the trailing twelve months (TTM) ended in Jan. 2025 was €-0.28.

During the past 3 years, the average EBIT per Share Growth Rate was -46.40% per year. During the past 5 years, the average EBIT per Share Growth Rate was -26.00% per year. During the past 10 years, the average EBIT per Share Growth Rate was 0.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Helix BioPharma's EBIT per Share or its related term are showing as below:

FRA:HBP0' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -46.4 Med: 8.5 Max: 19.7
Current: -46.4

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Helix BioPharma was 19.70% per year. The lowest was -46.40% per year. And the median was 8.50% per year.

FRA:HBP0's 3-Year EBIT Growth Rate is ranked worse than
91.56% of 1232 companies
in the Biotechnology industry
Industry Median: 7.85 vs FRA:HBP0: -46.40

Helix BioPharma's EBIT for the three months ended in Jan. 2025 was €-0.92 Mil.

Helix BioPharma EBIT per Share Historical Data

The historical data trend for Helix BioPharma's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Helix BioPharma EBIT per Share Chart

Helix BioPharma Annual Data

Trend

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

Jul24

EBIT per Share

Get a 7-Day Free Trial

-0.22

-0.23

-0.17

-0.56

-0.70

Helix BioPharma Quarterly Data
	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25
EBIT per Share	Get a 7-Day Free Trial															-0.07	-0.03	-0.07	-0.09	-0.09

Helix BioPharma EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Helix BioPharma's EBIT per Share for the fiscal year that ended in Jul. 2024 is calculated as

	EBIT per Share		(A: Jul. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-6.224	/	8.897
=	-0.70

Helix BioPharma's EBIT per Share for the quarter that ended in Jan. 2025 is calculated as

	EBIT per Share		(Q: Jan. 2025 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-0.921	/	10.013
=	-0.09

EBIT per Share for the trailing twelve months (TTM) ended in Jan. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.28

Helix BioPharma (FRA:HBP0) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Helix BioPharma EBIT per Share Related Terms

Thank you for viewing the detailed overview of Helix BioPharma's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Helix BioPharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Helix BioPharma Corp (FRA:HBP0) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

HBP:Canada

Address

40 Temperance Street, Suite 2700, Bay Adelaide Centre - North Tower, Toronto, ON, CAN, M5H0B4

Website

https://www.helixbiopharma.com

Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidate is L-DOS47 for Tumor Defence Breaker is in clinical trials for pancreatic cancer.

Helix BioPharma Headlines

No Headlines